Y-mAbs Therapeutics (YMAB) PT Lowered to $11 at Morgan Stanley
Tweet
Share
E-mailGet Alerts YMAB Hot Sheet
Price: $8.61 --0%
Rating Summary:
5 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 9
Rating Summary:
5 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 9
Join SI Premium – FREE
Morgan Stanley analyst Michael Ulz lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $11.00 (from $12.00) while maintaining a Underweight rating.
You May Also Be Interested In
- Berenberg Downgrades PolyPeptide Group AG (PPGN:SW) to Hold
- Banco Bilbao Vizcaya Argentaria SA (BBVA:SM) (BBVA) PT Raised to EUR26.80 at JPMorgan
- Nordea Bank Abp (NDA:SS) (NRDBY) PT Raised to SEK167 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
